Introduction
============

*Clostridium difficile* is a Gram-positive, spore-forming, motile and strict anaerobe rod that can be found in the gastrointestinal tract of humans and animals ([@B20]). The current classification of the "Bergey's Manual of Systematic Bacteriology" includes *C. difficile* in the Phylum *Firmicutes*, Class *Clostridia*, Order *Clostridiales* and Family *Peptostreptococcaceae* ([@B28]). A recent taxonomic study, based on 16S rRNA and ribosomal protein sequences, ascertains that *C. difficile* belongs to this family and proposes that it should be renamed as *Peptoclostridium difficile* ([@B56]); this new name appears in the taxonomic classification and nomenclature catalog of NCBI^[1](#fn01){ref-type="fn"}^, but still *C. difficile* remains as the name recognized by the clinical and scientific community.

*C. difficile* infection (CDI) is the main cause of diarrhea associated with antibiotic use or related to health-care environments ([@B25]) and increasing incidence is reported among populations previously considered as low risk, such as pregnant women and children ([@B10]). The ubiquity of this bacterium, in combination with its capability to form spores, makes hospital environments a good source for *C. difficile* acquisition, although zoonotic ([@B5]) and food transmissions ([@B46]) have been proposed as well. The incidence and severity of CDI has been growing since the beginning of this century due to the global occurrence of hypervirulent strains such as BI/NAP1/027 (group BI by restriction endonuclease analysis, North American pulse-field type NAP1 by pulse-field gel electrophoresis, and ribotype 027; [@B36]; [@B52]). The antibiotics metronidazole and vancomycin are the current treatments for CDI, but this does not prevent the high rates of recurrence. Thus, new emerging therapeutic options, such as fecal microbiota transplantation (FMT), new antibiotics, bacteriocins, bacteriophages, and probiotics are under evaluation for the control of CDI ([@B30]; [@B15]; [@B31]). Indeed probiotics, which are "live microorganisms that, when administered in adequate amounts, confer a health benefit on the host" ([@B16]; [@B18]), have been proposed as biotherapeutic agents to help microbiota restoration after a dysbiosis caused by antibiotics or infections ([@B34]).

The information encoded on the genomes of this species, excellently reviewed by [@B21], reveals high plasticity and very low levels of conservation among strains. This genetic diversity is reflected in its physiological adaptation to different ecosystems and in the occurrence of different phenotypes. In addition, the presence of a wide variety of transposons and phages explain the lineage evolution of clinically relevant loci, such as the antimicrobial resistance genes and the PaLoc (pathogenicity locus), among others ([@B21]). The PaLoc harbors, together with three additional genes, *tcdA* and *tcdB* coding for toxin A and toxin B, respectively, which are the major *C. difficile* virulence factors ([@B32]). The modulating environmental signals regulating the expression of PaLoc is not totally understood and a recent report shows that toxin synthesis is regulated through quorum-sensing signaling ([@B13]). TcdA and TcdB are large toxins whose main mechanism of action is known, although host receptors and toxin-mediated responses still remain to be fully deciphered. They act as intracellular glycosyltransferases modifying the Ras superfamily of small GTPases thus inducing intracellular changes, including *F*-actin condensation, transcriptional activation and cell apoptosis of intestinal epithelial cells. This promotes the disruption of the tight junctions and barrier integrity, leading to an increase in the gut permeability and neutrophil infiltration. Downstream effects also include modifications in the chemokine and cytokine production patterns toward an inflammatory response and fluid accumulation, ending with the clinical manifestations of leukocytosis and diarrhea ([@B51]; [@B14]; [@B9]; [@B26]). Therefore, anti-toxin therapies to counteract the negative effects of these potent *C. difficile* virulence factors could be valuable tools to reduce the course of CDI ([@B43]).

In a previous study we developed a biological model, using the (human) intestinal epithelial cell line HT29, to follow in real time the effect of supernatants collected from *C. difficile* cultures of a TcdA+, TcdB+ (toxinotype 0) strain. This method is based on the continuous monitoring of the impedance signal, transmitted through gold microelectrodes placed in the bottom of microtiter plates, of HT29 monolayers ([@B48]). Our aim in the present work is to search for lactobacilli and bifidobacteria probiotic candidates with anti-toxin capability able to protect HT29 cells from the cytotoxicity caused by toxigenic *C. difficile* supernatants.

Materials and Methods {#s1}
=====================

Bacterial Strains and Culture Conditions
----------------------------------------

The *Bifidobacterium* and *Lactobacillus* species used in this study are listed in **Table [1](#T1){ref-type="table"}**. Most strains belonging to IPLA culture collection were isolated from infant feces and breast milk ([@B42]), whereas IPLA20031 and IPLA20032 were obtained after adaptation to increasing concentrations of bile salts from a parental strain isolated from a dairy product ([@B35]). Strains were grown in MRSC \[MRS (Biokar Diagnostics, Beauvois, France) supplemented with 0.25% [L]{.smallcaps}-cysteine (Sigma-Chemical Co., St. Louis, MO, USA)\] at 37°C in the anaerobic chamber MG500 (Don Whitley Scientific, Yorkshire, UK) under 80% N~2~, 10% CO~2~ and 10% H~2~ atmosphere. As standard procedure bacterial stocks, kept at -80°C in MRSC + 20% glycerol, were spread onto the surface of agar-MRSC and incubated for 3 days. A single colony was picked to inoculate MRSC broth which, after 24 h incubation, was used to inoculate (2%) 10 ml fresh MRSC broth. This culture was incubated overnight (18 h) to prepare the bacterial suspensions that will be described next.

###### 

Strains included in this study and normalized cell index (CI) obtained at 4 and 22 h after addition of neutralized cell-free supernatants (NCFS) collected from incubations of each bifidobacteria or lactobacilli strain with 2.5% of toxigenic *Clostridium difficile* LGM21717 supernatant (Tox-S).

                                                     Mean ± SD                                   
  ----------------------------- -------------------- -------------- -------------- ------------- -------------
  *C. difficile* Tox-S (2.5%)   LMG21717^∗^          -0.64 ± 0.13   -0.93 ± 0.11   4.41 ± 0.01   0.48 ± 0.0
  *B. bifidum*                  LMG13195^∗^          -0.62 ± 0.13   -0.97 ± 0.10   4.05 ± 0.33   0.15 ± 0.01
                                IPLA20024            -0.43 ± 0.12   -0.92 ± 0.10   2.87 ± 0.02   0.11 ± 0.01
                                IPLA20025            -0.64 ± 0.08   -1.03 ± 0.07   3.47 ± 0.09   0.14 ± 0.02
                                IPLA20017            -0.71 ± 0.11   -1.04 ± 0.07   3.50 ± 0.12   0.42 ± 0.01
  *B. animalis*                 DSM15954^†^ (Bb12)   -0.58 ± 0.09   -1.00 ± 0.13   3.71 ± 0.33   0.41 ± 0.04
                                IPLA20031 (A1dOx)    -0.53 ± 0.05   -1.04 ± 0.07   4.60 ± 0.48   0.58 ± 0.26
                                IPLA20032 (A1dOxR)   -0.64 ± 0.11   -1.00 ± 0.12   4.32 ± 0.3    0.42 ± 0.03
                                IPLA20020            -0.62 ± 0.07   -1.05 ± 0.08   4.08 ± 0.42   0.42 ± 0.04
  *B. longum*                   IPLA20021            -0.16 ± 0.11   -0.60 ± 0.20   1.50 ± 0.14   0.29 ± 0.14
                                IPLA20022            -0.06 ± 0.05   -0.06 ± 0.12   0.54 ± 0.18   0.26 ± 0.04
                                IPLA20001            -0.09 ± 0.06   -0.33 ± 0.19   1.71 ± 0.05   0.26 ± 0.04
                                IPLA20002            -0.07 ± 0.08   -0.57 ± 0.09   1.25 ± 0.16   0.22 ± 0.05
  *B. breve*                    IPLA20004            -0.00 ± 0.04   -0.24 ± 0.12   0.75 ± 0.09   0.21 ± 0.08
                                IPLA20005            -0.03 ± 0.03   -0.25 ± 0.09   0.56 ± 0.29   0.15 ± 0.01
                                IPLA20006            -0.12 ± 0.01   -0.66 ± 0.08   1.05 ± 0.37   0.12 ± 0.01
  *B. pseudocatenulatum*        IPLA20026            -0.45 ± 0.06   -0.91 ± 0.13   3.31 ± 0.02   0.40 ± 0.12
  *L. crispatus*                IPLA20120            -0.44 ± 0.06   -0.91 ± 0.00   4.09 ± 1.64   0.22 ± 0.09
  *L. gasseri*                  IPLA20121            -0.42 ± 0.04   -0.91 ± 0.03   3.68 ± 1.28   0.43 ± 0.16
  *L. paracasei*                IPLA20124            -0.39 ± 0.03   -0.83 ± 0.03   4.57 ± 0.26   0.46 ± 0.03
  *L. rhamnosus*                LMG18243^∗^ (GG)     -0.41 ± 0.03   -0.83 ± 0.03   3.35 ± 0.44   0.42 ± 0.04
                                                                                                 

∗

LMG: Belgian Coordinated Collections of Microorganisms" (BCCM, Gent, Belgium).

†

DSM: German Collection of Microorganisms and Cell cultures (DSMZ, Braunschweig, Germany).

The remnant toxins in these NCFS were quantified by ELISA tests. Data were obtained from two biological replicates each measured by duplicate.

The strain *C. difficile* LMG21717 (∼ATCC9689, Ribotype 001, genes *tcdA*+, *tcdB*+, *cdtB*-) producing both TcdA and TcdB toxins (Toxinotype 0) was purchased from the "Belgian Coordinated Collections of Microorganisms" (BCCM, Gent, Belgium). The strain was routinely grown in Reinforced Clostridium Medium (RCM, Oxoid, Thermo Fisher Scientific Inc., Waltham, MA, USA) in Hungate tubes under anaerobic conditions at 37°C. Frozen stocks (-80°C in RCM + 20% glycerol) were directly activated in RCM broth incubated for 24 h and this culture was used to inoculate (2%) fresh medium that was cultivated for 13 h. This culture was used as inoculum to obtain the toxigenic supernatant.

### Preparation of Toxigenic *C. difficile* Supernatant

Conditions to obtain toxigenic supernatant from *C. difficile* LMG21717 have previously been determined and published ([@B48]). In short, 300 μl of RCM grown culture were used to inject into Hungates tubes containing 15 ml of Gifu Anaerobic Medium (GAM, Nissui Pharmaceutical Co., Ltd., Tokyo, Japan). GAM cultures were incubated for 48 h and centrifuged (16,000 × *g*, 10 min) to obtain the *C. difficile-*free toxigenic supernatant (Tox-S), which was kept in several aliquots at -80°C.

Two independent ELISA tests (tgcBIOMICS GmbH, Bingen, Germany) were used to quantify the concentration of TcdA or TcdB in the toxigenic supernatant, as well as the remnant toxins in the neutralized bacterial-supernatants obtained after incubation of Tox-S with bifidobacteria and lactobacilli.

### Incubation of Bifidobacteria or Lactobacilli with Toxigenic *C. difficile* Supernatant

The experimental design carried out in this study is schematized in **Supplementary Figure [S1A](#SM1){ref-type="supplementary-material"}**. Bifidobacteria and lactobacilli cultures grown for 18 h in MRSC were washed twice with PBS and resuspended at 10^9^ cfu/ml in the HT29-cultivation medium (MM, described below) supplemented with 5% of Tox-S from *C. difficile* or without supplementation (controls). After incubation for 1 h under anaerobic conditions and mild stirring (∼300 rpm), the bacterial suspensions were centrifuged (16,000 × *g*, 10 min) to obtain bifidobacteria- or lactobacilli-free bacterial supernatants. Then, the pH was increased to 7.55 ± 0.05 with 1 and 0.1 N NaOH and the volume obtained was adjusted to twice the initial one with MM; this means that the maximum amount of remnant toxin that could be present was 2.5%. These neutralized cell-free supernatants (NCFS) were directly used to test their cytotoxicity upon HT29 monolayers as well as to quantify the remnant TcdA and TcdB toxins. This screening was performed with two biological replicates, each analyzed in duplicate, of each bacterial strain using HT29 monolayers of two consecutive passages (p147 and p148).

### Incubation of Dead and Live *B. longum* IPLA20022 with Toxigenic *C. difficile* Supernatant

The strain *B. longum* IPLA20022 was selected in order to determine whether the capability to diminish the cytotoxic effect of *C. difficile* supernatant was dependent on bacterial viability. For that purpose UV-treated IPLA20022 suspensions were prepared from MRSC-grown cultures that were washed and resuspended in PBS at 10^9^ cfu/ml. Then, the PBS suspension was poured into several petri dishes allowing a high surface spread and they were submitted to ultra violet radiation in a UV-chamber (15W, Selecta, Barcelona, Spain). Three UV cycles of 30 min were applied, homogenizing the PBS suspension in each interval, and the absence of viability was checked by plating serial dilutions of UV-treated IPLA20022 suspension in agar-MRSC ([@B27]). Incubation of this UV-treated suspension (dead IPLA20022) with toxigenic *C. difficile* supernatant was performed as previously described. A non UV-killed suspension (live IPLA20022) of the same culture was used as control. After incubation for 1 h, both suspensions were processed to obtain the respective NCFS (**Supplementary Figure [S1A](#SM1){ref-type="supplementary-material"}**). This experiment was carried out with three independent cultures (biological replicates) of strain IPLA20022 upon HT29 monolayers within the same passage (p149), each measured in duplicate.

### Incubation of Supernatants from *B. longum* IPLA20022 with Toxigenic *C. difficile* Supernatant

To test the activity of putative secreted factors by *B. longum* IPLA20022 against *C. difficile* toxins, cell-free bifidobacterial supernatants obtained from three independent-culture replicates (each analyzed in duplicate) were incubated with 50% toxigenic (Tox-S) supernatant for 1 h under anaerobic conditions. Afterward, supernatants were neutralized (pH ≥ 7.5) and its cytotoxic activity tested upon HT29 monolayers (passage p149) at 2.5% in MM (**Supplementary Figure [S1B](#SM1){ref-type="supplementary-material"}**).

Intestinal Epithelial Cell Line HT29 and Culture Conditions
-----------------------------------------------------------

The intestinal cell line HT29 (ECACC 91072201), from human colon adenocarcinoma, was purchased from the "European Collection of Cell Cultures" (Salisbury, UK) and stored at IPLA under liquid N~2~. McCoy's Medium (MM) supplemented with 10% foetal bovine serum (FBS), 3 mM [L]{.smallcaps}-glutamine and a mixture of antibiotics (50 μg/ml streptomycin-penicillin, 50 μg/ml gentamicin and 1.25 μg/ml amphotericin B) was used for HT29 cultivation. The pH value of supplemented MM was 7.48 ± 0.02. All media and reagents were purchased from Sigma--Aldrich. Maintenance of the cell line, between passages 145 to 149, was performed under standard conditions, at 37°C 5% CO~2~ atmosphere, in a CO2-Series Shel-Lab incubator (Sheldon Manufacturing Inc., OR, USA).

Monitoring Behavior of HT29 in RTCA
-----------------------------------

The real time cell analyzer (RTCA-DP) xCelligence (ACEA Bioscience Inc., San Diego, CA, USA) used to monitor HT29 cells performance upon the different conditions tested, was introduced in a Heracell-240 Incubator (Thermo Electron LDD GmbH, Langenselbold, Germany) set at 37°C with 5% CO~2~ atmosphere. This technology records variations in impedance due to the adhesion, growth and morphological changes of HT29 cells during interaction with gold-microelectrodes placed in the bottom of specific microtiter plates (E-plates). The impedance signal is converted in the arbitrary "cell index" (CI) unit which is recorded in the external computer allowing, as well, data analyses through the RTCA software 1.2.1 (ACEA Bioscience).

The method to monitor the damage caused by *C. difficile* toxins was previously described by [@B48]. In short, 16-well E-plates were seeded with 2 × 10^5^ HT29 cells (in 100 μl) and monitored (recording signal every 15 min) for 22 h to ensure the formation of a monolayer (confluent state). Afterward, the medium was removed and 200 μl of the different bacterial NCFS were added per well. Additionally, wells containing 200 μl of a control without bacteria but with Tox-S (added at 2.5% in MM, cytotoxic control) or 200 μl MM medium without bacteria or Tox-S added (non-cytotoxic control) were included in each experiment. The monitoring continued (every 10 min) for an additional 20--22 h under standard incubation conditions. CI values recorded were normalized by the time of the supernatant addition and by the control sample (MM) as previously described ([@B48]). Samples of each bacterial supernatant were obtained from, at least, duplicated biological experiments (two independent Tox-S vs. bifidobacteria or lactobacilli incubations) and each NCFS was tested in duplicate (two independent wells within the same E-plate). Thus, four normalized-CI data were obtained per each bacterial strain tested.

Image Analysis of HT29 Behavior
-------------------------------

### Time-Lapsed Monitoring in Real Time

Several images were captured in real time using the compact, inverted, optical microscope (40× objective) LumaScope-600 Series (Etaluma, Carlsbad, CA, USA) which was placed inside the Heracell-240 incubator. Images were recordered in an external computer with the software LumaView600Cy 13.7.17.0 (Etaluma). To this end, 2-well μ-Slide (ibiTreat, 1.5 polymer coverslip, tissue culture treated, sterilized slides, Ibidi GmbH, Martinsried, Germany) were seeded with 2 × 10^6^ HT29 cells/ml (1 ml) and placed on top of the microscope objective. Images were recorded every 15 min until the confluent state was reached (about 22 h); afterward, culture medium was removed and 1 ml of fresh medium containing 2.5% Tox-S or 1 ml of the NCFS collected after incubation of live *B. longum* IPLA20022 with Tox-S, was added in two independent μ-Slides. Image capture was performed for additional an 16 h.

### End-Point CSLM Analysis

HT29 monolayers submitted to different treatments were analyzed by confocal scanning laser microscopy (CSLM) after an end-point incubation period of 20 h. For this, 8-well μ-Slide (ibiTreat, Ibidi GmbH) were seeded with 2 × 10^6^ HT29 cells/ml (0.3 ml) and incubated for 22 h to reach confluent state. Afterward, supernatant was removed and wells (in duplicate) were filled with the same volume of fresh medium containing MM (control), 2.5% Tox-S, and NCFS from live or dead *B. longum* IPLA20022 incubated with Tox-S. Incubation continued for additional 20 h; then, supernatant of each well was removed and HT29 monolayers fixed with 1 vol (0.3 ml) of cold (-20°C) acetone for 10 min. Samples were washed twice with PBS for 5 min under mild stirring and permeabilised with PBS containing 0.1% Triton 100x (Sigma) for 15 min. The nonspecific binding sites were blocked with FBS (25% in PBS) for 20 min and finally washed once with PBS. The Phalloidin-Alexa-Fluor-568 probe (Molecular Probes-Thermo Fisher, Life Technologies S.A., Madrid, Spain) toward *F*-actin was added in 0.3 ml of PBS (final concentration of 25 μl/ml) and samples were incubated overnight at 4°C in darkness. After washing twice with PBS, HT29 nucleus were stained with DAPI probe (Merck-Millipore Cor., Billerica, MA, USA) used at 1:1000 (final dilution in PBS) and incubated under the same conditions for, at least, 6 h. Finally, samples were washed and added to 0.3 ml of PBS previous visualization under microscope.

For the CSLM analysis the Leica TCS AOBS SP8 X confocal microscopy (Leica Microsystems GmbH, Heidelberg, Germany) located in the Scientific-Technical Services of Oviedo University, was used. DAPI and Alexa-Fluor-568 fluorochromes were excited at 405 nm by a blue--violet laser diode and at 578 nm by a white light laser, respectively. *Z*-stacks of HT29 samples were acquired using a 63x/1.4 oil objective applying a line average of 2 to reduce noise on the final images and a z-step of 1 micron. Details of a region were later acquired using a 2.50 optical zoom. Image-captures were recorded with the "Leica Application Suite X" software version 1.8.1.13759 (Leica).

Statistical Analysis
--------------------

To assess differences in the response (normalized CI) of HT29 due to the anti-toxin activity of *B. longum* IPLA20022, one-way ANOVA followed by SNK (Student-Newman--Keuls, *p* \< 0.05) mean comparison tests were performed. The statistical package IBM SPSS Statistics for Window Version 22.0 (IBM Corp., Armonk, NY, USA) was used to carry out these analyses. Legend of **Figure [4](#F4){ref-type="fig"}** describes the comparisons made in each type of experiment.

Results
=======

The method previously developed by our group to detect in real time the toxic effect of *C. difficile* upon intestinal cell lines was used to address the anti-toxin probiotic potential of twenty bifidobacteria and lactobacilli strains. As an initial step several parameters were optimized in order to establish conditions for the screening using as a biological model confluent-HT29 monolayers (data no shown). Finally, neutralized (pH ≥ 7.5) cell-free supernatants (NCFS), obtained after incubation (1 h, 37°C, anaerobiosis) of each strain (about 1 × 10^9^ cfu/ml) with 5% *C. difficile* supernatant (Tox-S), were used for this study (**Supplementary Figure [S1A](#SM1){ref-type="supplementary-material"}**). The behavior of HT29 monolayers was monitored in real time recording the variations in the impedance signal (normalized-CI) over time due to the presence of the NCFS, the toxigenic control (2.5% Tox-S), or the culture media alone (MM; **Figure [1](#F1){ref-type="fig"}**). To understand the impedance graphs is worth noting that the lowest normalized-CI value indicates the highest toxigenic capability of *C. difficile* supernatant upon HT29; thus, in **Figure [1](#F1){ref-type="fig"}**, the red line (representing values obtained with 2.5% Tox-S) is the control for damage, whereas the pink line represents the non-toxigenic control (MM) used as a reference for normalization of all CI values being the reason to have "0 value." Regarding the effect of NCFS, those obtained after incubation of strains in MM medium without *C. difficile* toxins (dotted lines) showed normalized-CI values equal or higher to the control, therefore indicating the absence of any toxic effect induced by the putative probiotics. However, when the NCFS obtained from bacteria incubated with Tox-S were analyzed, HT29 monolayers behaved differently depending on the species considered (**Figure [1](#F1){ref-type="fig"}**). Graphics obtained clearly show that strains belonging to species *Bifidobacterium bifidum* and *B. animalis* subsp. *lactis* had no protective effect against *C. difficile* toxins since the normalized-CI lines obtained showed similar, or even lower, values than the toxigenic Tox-S control. By contrast, the normalized-CI obtained from the four lactobacilli tested, as well as the strains of *B. longum*, *B. breve*, and *B. pseudocatenulatum* were higher than those induced by *C. difficile* supernatant. In general, normalized-CI lines from *B. longum* and *B. breve* strains were the closest to the control, thus being the strains showing higher anti-toxin capability.

![**Variation in the normalized cell index (Normalized-CI) of HT29 monolayers treated with different neutralized cell-free supernatants (NCFS; neutralized cell-free supernatants) obtained in a representative experiment after incubation of toxigenic *Clostridium difficile* supernatant (Tox-S) with different strains of *Bifidobacterium* and *Lactobacillus* species.** The Tox-S was tested alone at 2.5% (red line). Normalization was performed with respect to the point of NCFS's addition and with respect to the control sample (culture medium MM without supernatant addition) which is the 0-reference control (pink line). The dotted lines represent results obtained with the NCFS obtained after incubation of the same strains in MM (without Tox-S). Representative SD values of these data are collected in **Table [1](#T1){ref-type="table"}**.](fmicb-07-00577-g001){#F1}

Normalized-CI obtained 4 h after NCFS addition (short term effect) or 22 h after (long term effect) were analyzed in more detail (**Table [1](#T1){ref-type="table"}**). Results obtained in the short term showed that all strains belonging to *B. longum* and *B. breve*, as well as *L. gasseri* IPLA20121, *L. paracasei* IPLA20124 and *L. rhamnosus* GG, seemed to have higher values of normalized-CI than the toxigenic control. However, none of the lactobacilli were able to keep the protective effect upon HT29 for a prolonged period (22 h). The strain *C. difficile* LMG21717 used in this study produced about ten-times more TcdA than TcdB (**Table [1](#T1){ref-type="table"}**) and the strains showing high protective effect were those that apparently were more effectively in reducing the concentration of TcdA, i.e., belonging to *B. longum* and *B. breve* species (**Table [1](#T1){ref-type="table"}**). Indeed, the NCFS obtained from strain *B. longum* IPLA20022 that promoted the lowest damage after 22 h only had 12% of remnant TcdA. Of note is that NCFS from *B. bifidum* and *B. breve* seemed to have a good ability to reduce TcdB levels (remnant between 23 and 44%), although this fact was not correlated with higher protective effect in *B. bifidum* because this species seemed to be less effective against TcdA.

Time-lapsed microphotographs (**Figure [2](#F2){ref-type="fig"}**) showed that HT29 cells treated with 2.5% toxigenic *C. difficile* supernatant become spherical and the integrity of the monolayer was lost when incubation was prolonged (**Figure [2A](#F2){ref-type="fig"}**). However, monolayers added with NCFS from live *B. longum* IPLA20022 incubated with Tox-S remained more stable and only after a long incubation period (16 h) some cellular particles were released to the culture medium (**Figure [2B](#F2){ref-type="fig"}**). Furthermore, although the cytopathic mechanism of *C. difficile* toxins is well known, we performed immunohistochemistry CSLM analysis to confirm the cellular events under different treatments (**Figure [3](#F3){ref-type="fig"}**). Control HT29 monolayers (grown in MM for 20 h) showed a typical *F*-actin cytoskeleton in which the nucleus is imbibed, thus having an epithelial-like morphology with annexed cells well connected. However, monolayers treated for the same period with Tox-S supernatant lost the interconnection among *F*-actin filaments (**Figure [3B](#F3){ref-type="fig"}**) and the nucleus seems to be in the initial stages of apoptosis, i.e., the chromatin initiates the condensation showing more intense blue due to DAPI staining (**Figure [3C](#F3){ref-type="fig"}** and **Supplementary Figure [S2](#SM2){ref-type="supplementary-material"}**); therefore, HT29 cells become more spherical (non-epithelial morphology) and it seems that the tight junctions that maintain the monolayer integrity might have been disrupted (**Figure [3A](#F3){ref-type="fig"}**). The photographs obtained from HT29 monolayer treated for 20 h with the NCFS from live *B. longum* IPLA20022 were more similar to the control without toxin; the *F*-actin cytoskeleton still showed an interconnected structure and the nucleus showed less intense DAPI staining comparable to that of the negative control than the toxigenic control. This structure, resembling that of intact epithelial monolayers, is in agreement with the presence of lower amounts of remnant toxin in the NCFS and higher normalized-CI due to the capability of this strain to counteract the effect of clostridial toxins.

![**Images of HT29 monolayers captured in real time (37°C, 5% CO~2~) with the inverted optical microscope (objective 40×) at three incubation times (0, 4, and 16 h).** Monolayer treated with toxigenic *C. difficile* supernatant (Tox-S, **A)** or with NCFS (neutralized cell-free supernatants) obtained after incubation of live *Bifidobacterium longum* IPLA20022 with Tox-S **(B)**.](fmicb-07-00577-g002){#F2}

![**Immunofluorescence images obtained by CSLM of HT29 after 20 h of incubation without toxigenic *C. difficile* supernatant Tox-S (control) and with Tox-S (damage control), and with NCFS (neutralized cell-free supernatants) obtained after incubation of live or dead *B. longum* IPLA20022 with Tox-S.** **(A)** and **(B)** show a *Z*-projection (thickness about 13--15 μm) of 10 XY-slides and **(C)** shows a CSLM-zoom of a XY-region. **(A)** and **(C)** show the combination of DAPI-stained nucleus (blue, excited at 405 nm by a blue--violet laser diode) and *F*-actin stained with Phalloidin-Alexa-Fluor-568 probe (red, excited at 578 nm by a white light laser); *F*-actin is also shown as a single channel in **(B)**. Bars 10 μm.](fmicb-07-00577-g003){#F3}

In order to determine whether this strain retains its anti-toxin capability under non-viable conditions, *B. longum* IPLA20022 suspension was irradiated with UV light for 90 min. The RTCA monitoring clearly showed that this treatment modified the protective effect of the bifidobacteria upon HT29 since the normalized-CI of the dead strain followed the same tendency as the toxigenic control (**Figure [4A](#F4){ref-type="fig"}**). Indeed, the statistical analysis performed at 4 and 22 h after NCFS addition showed that live IPLA20022 had a significantly (*p* \< 0.05) higher normalized-CI, i.e., higher protective capability, than the dead strain and the toxigenic control (**Figure [4A](#F4){ref-type="fig"}**). Consequently, the immunohistochemistry study confirmed that the morphology of HT29 treated for 20 h with the NCFS from dead *B. longum* IPLA20022 was more similar to that obtained with the toxigenic control (**Figure [3](#F3){ref-type="fig"}**). Indeed, besides the *F*-actin modification, some apoptotic bodies were evidenced in both toxigenic and dead-IPLA20022 samples (**Supplementary Figure [S2](#SM2){ref-type="supplementary-material"}**) suggesting that the UV treatment of this strain, which probably affected the structure and function of the cell envelope, abolished the anti-clostridial effect of *B. longum* IPLA20022. Finally, we have tested the activity against clostridial toxins of the supernatants obtained from overnight cultures of this bifidobacterial strain. Surprisingly, the normalized-CI values were similar to those of those obtained with (live) pellets and both of them were statistically (*p* \< 0.05) higher than the toxigenic control (**Figure [4B](#F4){ref-type="fig"}**). This result suggests that *B. longum* IPLA20022 is able to secrete factors having activity against the toxins of *C. difficile*.

![**Evolution of the normalized cell index (CI) of HT29 monolayers treated with NCFS (neutralized cell-free supernatants) obtained after incubation of toxigenic *C. difficile* supernatant (Tox-S) with live or dead *B. longum* IPLA20022 **(A)**.** Evolution of the normalized-CI of HT29 monolayers treated with 2.5% of neutralized supernatant obtained after incubation of toxigenic *C. difficile* supernatant (Tox-S) with *B. longum* IPLA20022 supernatant **(B)**. Normalization was performed with respect to the point of NCFS's addition and with respect to the control sample (culture medium MM without supernatant addition) which is the 0-reference line (pink line). The dotted lines represent results obtained with the NCFS obtained after incubation of the live or dead *B. longum* IPLA20022 or culture supernatant in MM (without Tox-S). Histograms located in the right of **(A)** and **(B)** sections, represented the mean and standard deviation of normalized-CI values obtained at 4 and 22 h from three biological replicates each measured in duplicate; within the same time, those means that do not share a common letter are statistically different (*p* \< 0.05) according to one-way ANOVA and the mean comparison SNK (Student-Newman--Keuls) test.](fmicb-07-00577-g004){#F4}

Discussion
==========

The search for novel approaches to treat or prevent CDI is a current "hot-topic" in which the scientific community is devoting much effort. Different approaches are under investigation, most of them toward restoring the dysbiotic intestinal microbiota following infection through FMT ([@B54]; [@B37]) or using a consortia of defined species ([@B24]), but also toward the application of new antibiotics ([@B3]; [@B50]) and drugs to treat infections ([@B33]), as well as vaccinations with non-toxigenic *C. difficile* strains ([@B40]) or anti-toxin antibodies ([@B53]). Probiotic bacteriotherapy is becoming an option for the prevention of *C. difficile* recurrent infection ([@B25]), and also for the attenuation of CDI symptoms. The choice of the appropriate probiotic against *C. difficile* is of pivotal relevance since, although some formulations seem to be promising ([@B2]), not all of them are efficient ([@B1]).

Probiotic action against CDI is based on different bacterial antagonistic mechanisms, such as competition for adhesion to gut mucosa ([@B4]; [@B57]) and for colonization of the intestinal environment ([@B23]), production of antimicrobial molecules ([@B39]; [@B17]) or modulation of intestinal inflammation ([@B7]). Another target for probiotic action is the reduction of toxicity caused by *C. difficile* ([@B44]). In any case, if one of the active strains would be administered as a probiotic therapy to CDI patients, then the effect would only be present as long as the probiotic is consumed since stable colonization of probiotics in humans has not been shown yet.

In our study, we have explored the capability of twenty lactobacilli and bifidobacteria to counteract the effect of toxins (TcdA and TcdB) from *C. difficile* LMG21717 (equivalent to ATCC9689). The method used, based on impedance measurement of HT29 monolayers ([@B48]), allowed a quick search of the strains showing the highest anti-toxin ability which those were belonging to *B. longum* and *B. breve* species. This fact suggests that some species-specific characteristics could account for the observed effect, although differences were also detected among strains within the same species. As far as we know, there are few comparative studies among different probiotic species; [@B45] co-cultivated two *C. difficile* strains (including ATCC9689) with twenty five bifidobacteria or lactobacilli and they found that the capability to antagonize the toxic effect upon Vero line (monkey fibroblast-like kidney cells) was strain dependent, but they did not report a species-efficacy association. Nevertheless, the experimental procedure used in our screening for detecting anti-toxicity was based on the incubation of the probiotic strains with a toxigenic supernatant from *C. difficile*, previous to analyze the effect of NCFS upon the biological model HT29. Then, *a priori*, the putative mechanisms that could be behind the anti-toxin capability detected with our approach are the modification of the *C. difficile* toxin and/or its availability for acting on the epithelial cells.

Some authors have reported that probiotics are able to reduce the activity of *C. difficile* toxins. [@B4] observed that *Lactobacillus delbrueckii* subsp. *bulgaricus* B-30892 releases bioactive components, of unknown nature, able to decrease the toxic effect of *C. difficile* ATCC9689 upon epithelial intestinal Caco2 cells. Similarly, *Lactococcus lactis* subsp. *lactis* CIDCA8221 secretes heat-sensitive products, higher than 10 kDa, that are not affected by treatment with proteases or protease-inhibitors, which were able to protect Vero cells from *C. difficile* toxins ([@B6]). *Saccharomyces boulardii* releases an extracellular serin-protease that was able to breakdown the toxin A, as well as to inhibit its binding to the receptor in the brush border of ileal tissue ([@B11]). In our case, analysis of the bioactivity of the supernatant collected from strain IPLA20022 directly incubated with the toxigenic *C. difficile* supernatant showed similar effect on HT29 than that obtained with the bifidobacterial pellet. Then, it seems that this strain secreted molecules able to reduce the cytotoxic effect of clostrial toxins. As far as we could find, no exo-proteases have been described for bifidobacteria and only a few peptidases have been characterized ([@B19]; [@B41]). Additionally, other molecules inducing conformational changes in proteins that disrupt the active site of other proteins, which could putatively be involved in the inactivation of *C. difficile* toxins, have been described; these are serpins (serin protein inhibitors) found in the genome of *B. longum* ([@B38]) and *B. breve* ([@B47]) and ion chelating agents such as the iron-chelating siderophores ([@B12]; [@B49]). Thus, further and extensive work will be needed in order to decipher the nature of the bifidobacterial secreted factors acting against *C. difficile* toxicity.

Regarding the adsorption as mechanism to reduce toxins activity, it has been demonstrated that the soluble S-layer protein from the surface of *L. kefir* strains diminish the damage of clostridial toxins upon Vero cells, suggesting a direct interaction between the S-layer and the toxins ([@B8]). However, as far as we could know, this type of protein cover has not been described for bifidobacteria. Additionally, cellular extracts from *L. acidophilus* GP1B were able to interfere with quorum-sensing signals from *C. difficile* and down-regulated expression of some virulence genes; both, cellular extract and *L. acidophilus* strain, were efficient in increasing the survival rate of animals in a CDI murine model ([@B55]). The lactic acid synthesized by this lactobacilli strain also had an inhibitory effect on *C. difficile* growth. Similarly, [@B22] reported a bactericidal effect induced by the lactic acid synthesized by *Streptococcus thermophilus* LMD-9 and, furthermore, non-inhibitory levels (10 mM) decreased the *tcdA* expression and toxin-A release. *In vivo* (CDI mouse model) treatment with live *S. thermophilus* showed a significant inverse correlation between levels of luminal lactic acid and *C. difficile* abundance in the murine gut, thus reducing the disease activity indexes of experimentation animals ([@B22]). In our experimental design, bifidobacteria were in contact for 1 h only with the toxigenic clostridial supernatant, but not with *C. difficile*, and the putative effect of the organic acids (lactate and/or acetate) produced in this short incubation period by lactobacilli or bifidobacteria was neutralized.

Based on the results describe in this article, the adsorption of toxins to the bifidobacterial surface as well as the presence of secreted molecules responsible for the anti-toxigenic effect observed, are both plausible mechanisms of action. Nevertheless bacterial viability, which may be also needed to keep a functional bifidobacterial envelope, is required in order to maintain the anti-clostridial activity. Finally, the highest anti-toxin capability of *B. longum* and *B. breve* strains (pointing to a species-dependent efficacy) suggests that some specific characteristics of these two phylogenetically close species ([@B29]) could account for the anti-clostridial toxicity. Further experiments must be performed in order to understand the mechanism of action behind bifidobacterial anti-*C. difficile* toxicity. Another interesting observation that will deserve further attention is the (apparently) better capability of *B. bifidum*, and to a lower extent of *B. breve*, to specifically reduce TcdB levels.

Conclusion
==========

In this work we have optimized a protocol to search for potential probiotics with anti-toxic activity against toxins synthesized by *C. difficile*. The impedance-based, RTCA xCelligence was a fast, reliable and efficient method for the screening of a large collection of bacteria allowing the selection of those strains with higher protection capability. In our case, strains from *B. breve* and *B. longum* showed the better performance, since they were able to reduce the levels of toxins from *C. difficile* supernatants. The best candidate to be used as probiotic to alleviate CDI was *B. longum* IPLA20022; this was the strain with the highest *in vitro* capability for reducing the levels of clostrial toxins, as well as for avoiding the cytopatic effect upon the intestinal epithelial cellular line HT29. Apart for elucidating the mechanism behind this anti-toxigenic capability, the next steps will be to study the efficacy of *B. longum* IPLA20022 in more complex *in vitro* and *in vivo* biological models before proposing its human application to treat CDI.
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**FIGURE S1 \| Final conditions used to perform the screening of the anti-*Clostridium difficile* cytotoxic activity upon HT29 monolayers of twenty bifidobacteria and lactobacilli strains (**A**).** Scheme of the flow-work followed to test the capability of *Bifidobacterium longum* IPLA20022 culture supernatant to act against toxigenic *C. difficile* supernatant **(B)** MRSC, MRS broth supplemented with 0.25% [L]{.smallcaps}-cysteine; MM, McCoy's Medium added with supplements and antibiotics described in material and methods section; NCFS, neutralized cell-free supernatant.
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**FIGURE S2 \| Immunofluorescence images obtained by CSLM of HT29 after 20 h of incubation without toxigenic *C. difficile* supernatant Tox-S (control) and with Tox-S (damage control), and with NCFS (neutralized cell-free supernatants) obtained after incubation of live or dead *B. longum* IPLA20022 with Tox-S.** Images show a CSLM-2.50 optical zoom of a XY-slide. Upper-part images show the combination of DAPI-stained nucleus (blue, excite at 405 nm by a blue--violet laser diode) and *F*-actin stained with Phalloidin-Alexa-Fluor-568 probe (red, excited at 578 nm by a white light laser) **(A)**. Bottom-part images show the same magnification view at the visible (transmitted light) channel **(B)**. Arrows indicates the apoptotic bodies. Bars 10 μm.
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